---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-038309"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:15:28.140997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports record FY22 revenue of $73.7M (+17% YoY); net loss narrows to $29.6M

## Summary
- Record total revenues of $73.7M for FY2022, up 17% from $63.1M in FY2021.
- Net loss of $29.6M ($1.69/share) vs $44.0M ($4.32/share) in prior year; Adjusted EBITDA -$7.3M.
- Phase 3 DFD-29 (rosacea) fully enrolled; topline data expected H1 2023; NDA filing H2 2023.
- Q4 2022 revenue $16.0M, down 9% YoY due to Targadox generic competition.
- SG&A expenses rose to $59.5M from $39.8M; R&D decreased to $10.9M from $16.6M.

## SEC filing metadata
- accession: 0001104659-23-038309
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/tm236285d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-038309
- JSON: https://secwatch.observer/filing/0001104659-23-038309.json
- Plain text: https://secwatch.observer/filing/0001104659-23-038309.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported fourth quarter and full year ended December 31, 2022 results: revenue Total revenues were $73.7 million for the full year 2022, net income Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022, EPS $1.69 per share basic and diluted.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: Total revenues were $73.7 million for the full year 2022
  - Net income: Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022
  - EPS: $1.69 per share basic and diluted
  - Result: reported results
  source text: Total revenues were $73.7 million for the full year 2022, a record high for the Company, compared to total revenues of $63.1 million for the full year 2021, representing 17% growth.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm
- Earnings Releases
  Journey Medical Corp reported fourth quarter ended December 31, 2022 results: revenue total revenues of $16.0 million for the fourth quarter of 2022, net income Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022, EPS $0.60 per share basic and diluted.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: total revenues of $16.0 million for the fourth quarter of 2022
  - Net income: Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022
  - EPS: $0.60 per share basic and diluted
  - Result: reported results
  source text: This includes total revenues of $16.0 million for the fourth quarter of 2022, compared to net revenues of $17.5 million generated in the fourth quarter of 2021, representing a 9% decline from period-to-period primarily due to generic competition for Targadox.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.